Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00514579 · ClinicalTrials.gov registry record · Phase 2
Adult Double Cord Blood Transplant Study
A Phase 2 study of Hematologic Malignancies and Cord Blood Stem Cell Transplantation, sponsored by Center for International Blood and Marrow Transplant Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 10
- Study locations
NCT00514579: Completed Phase 2 study of Hematologic Malignancies and Cord Blood Stem Cell Transplantation, sponsored by Center for International Blood and Marrow Transplant Research.
NCT00514579 is a Phase 2 study of Hematologic Malignancies and Cord Blood Stem Cell Transplantation that has completed, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 56 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00514579, a Phase 2 study of Hematologic Malignancies and Cord Blood Stem Cell Transplantation, has completed, sponsored by Center for International Blood and Marrow Transplant Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 10
- Study locations
Study Summary
The hypothesis of the study is double unit umbilical cord blood transplantation in adults will be associated with a one year survival rate of at least 40%.
Conditions Studied
Interventions
- PROCEDURE Cord blood transplantation
Study Locations (10)
California
- City of Hope - Duarte
- University of California at Los Angeles - Los Angeles
Ohio
- Case Western Reserve University - Cleveland
- Ohio State University Medical Center - Columbus
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Blood and Marrow Transplant Program at Northside Hospital - Atlanta
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University Medical Center - Durham
Oklahoma
- University of Oklahoma - Oklahoma City
Wisconsin
- University of Wisconsin-Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
What the finished NCT00514579 record still lists
NCT00514579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Cord blood transplantation is the first listed.
NCT00514579 lists 10 locations in 8 states (California, Ohio, Florida).
Frequently Asked Questions
What is clinical trial NCT00514579 about?
NCT00514579 is a clinical study titled "Adult Double Cord Blood Transplant Study". The hypothesis of the study is double unit umbilical cord blood transplantation in adults will be associated with a one year survival rate of at least 40%.
What is the current status of trial NCT00514579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2007-08. Estimated completion is 2013-08.
What conditions does trial NCT00514579 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Cord Blood Stem Cell Transplantation.
What interventions are being tested in trial NCT00514579?
The interventions under investigation include: Cord blood transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00514579?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00514579 being conducted?
This trial has 10 study locations across California, Florida, Georgia, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00514579's enrollment target sits among peer trials
56 22nd of 45 higher than 24 of 45 other Hematologic Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
RECRUITING · Phase 2
-
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
RECRUITING · Phase 2
-
IVIG for Infection Prevention After CAR-T-Cell Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia